- $9.43bn
- $16.74bn
- $8.20bn
- 72
- 90
- 57
- 86
Annual income statement for Solventum, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 7,281 | 8,171 | 8,130 | 8,197 |
| Cost of Revenue | ||||
| Gross Profit | 4,315 | 4,923 | 4,695 | 4,693 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 5,851 | 6,292 | 6,437 | 6,505 |
| Operating Profit | 1,430 | 1,879 | 1,693 | 1,692 |
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 1,440 | 1,882 | 1,692 | 1,667 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 1,138 | 1,460 | 1,343 | 1,346 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 1,138 | 1,460 | 1,343 | 1,346 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 1,138 | 1,460 | 1,343 | 1,346 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 6.6 | 8.47 | 7.79 | 7.8 |